Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Reviews in Endocrine and Metabolic Disorders
Erschienen in: Reviews in Endocrine and Metabolic Disorders 4/2016

18.06.2016

Inositol(s) in thyroid function, growth and autoimmunity

verfasst von: Salvatore Benvenga, Alessandro Antonelli

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Myo-inositol and phosphatidylinositol(s) play a pivotal function in many metabolic pathways that, if impaired, impact unfavorably on human health. This review analyzes several experimental and clinical investigations regarding the involvement of this class of molecules in physiological and pathological situations, with a major focus on thyroid. Central issues are the relationship between phosphatidylinositol and thyrotropin (TSH) signaling on one hand, and phosphatydylinositol and autoimmunity on the other hand. Other issues are the consequences of malfunction of some receptors, such as those ones for TSH (TSHR), insulin (IR) and insulin-like growth factor-1 (IGF-1R), or the connection between serum TSH concentrations and insulin resistance. Also covered are insulin resistance, metabolic syndrome and their allied disorders (diabetes, polycystic ovary syndrome [PCOS]), autoimmunity and certain malignancies, with their reciprocal links. Myoinositol has promising therapeutic potential. Appreciation of the inositol pathways involved in certain disorders, as mentioned in this review, may stimulate researchers to envisage additional therapeutic applications.
Literatur
1.
Murthy PP. Structure and nomenclature of inositol phosphates, Phosphoinositides, and Glycosylphosphatidylinositols. Subcell Biochem. 2006;39:1–19.CrossRefPubMed
2.
Kompanje EJ, Jansen TC, van der Hoven B, Bakker J. The first demonstration of lactic acid in human blood in shock by Johann Joseph Scherer (1814-1869) in January 1843. Intensive Care Med. 2007;33:1967–1.CrossRefPubMedPubMedCentral
3.
Buttner J. Johann Joseph von Scherer (1814-69). The early history of clinical chemistry. J Clin Chem Clin Biochem. 1978;16:478–83.PubMed
4.
Hartig T. Über das Klebermehl Botanische Zeitung. 1855;13:881–2.
5.
Clements Jr RS, Darnell B. Myo-inositol content of common foods: development of a high-myo-inositol diet. Am J Clin Nutr. 1980;33:1954–67.PubMed
6.
Hooper NM. Glycosyl-phosphatidylinositol anchored membrane enzymes. Clin Chim Acta. 1997;266:3–12.CrossRefPubMed
7.
Di Paolo G, De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature. 2006;443:651–7.CrossRefPubMed
8.
9.
Downes CP. Twenty-fifth Colworth medal lecture. The cellular functions of myo-inositol. Biochem Soc Trans. 1989;17:259–68.CrossRefPubMed
10.
Downes CP, Macphee CH. Myo-inositol metabolites as cellular signals. Eur J Biochem. 1990;193:1–18.CrossRefPubMed
11.
Kopp P. Thyroid hormone synthesis. In: Braverman LE, Cooper DS, editors. Werner and Ingbar’s The Thyroid: a fundamental and clinical text. Philadelphia: Wolters Kluwer Lippincott Williams & Wilkins, 10th edition, 2013. pp. 48–74.
12.
Corvilain B, Laurent E, Lecomte M, Vansande J, Dumont JE. Role of the cyclic adenosine 3′,5′-monophosphate and the phosphatidylinositol-Ca2+ cascades in mediating the effects of thyrotropin and iodide on hormone synthesis and secretion in human thyroid slices. J Clin Endocrinol Metab. 1994;79:152–9.PubMed
13.
Song Y, Driessens N, Costa M, De Deken X, Detours V, Corvilain B, Maenhaut C, Miot F, Van Sande J, Many MC, Dumont JE. Roles of hydrogen peroxide in thyroid physiology and disease. J Clin Endocrinol Metab. 2007;92:3764–73.CrossRefPubMed
14.
Grasberger H, Van Sande J, Hag-Dahood Mahameed A, Tenenbaum-Rakover Y, Refetoff S. Brief report: a familial thyrotropin (TSH) receptor mutation provides in vivo evidence that the inositol phosphates/Ca2+ cascade mediates TSH action on thyroid hormone synthesis. J Clin Endocrinol Metab. 2007;92:2816–20.
15.
Field JB, Ealey PA, Marshall NJ, Cockcroft S. Thyroid-stimulating hormone stimulates increases in inositol phosphates as well as cyclic AMP in the FRTL-5 rat thyroid cell line. Biochem J. 1987;247:519–24.CrossRefPubMedPubMedCentral
16.
de Oliveira M, Luvizotto Rde A, Olimpio RM, De Sibio MT, Conde SJ. Biz Rodrigues Silva C, Moretto FC, Nogueira CR. Triiodothyronine increases mRNA and protein leptin levels in short time in 3 T3-L1 adipocytes by PI3K pathway activation. PLoS ONE. 2013;8:e74856.CrossRefPubMedPubMedCentral
17.
Spaulding SW. Biological actions of thyrotropin. In: Braverman LE, Cooper DS, editors. Werner and Ingbar’s The Thyroid: a fundamental and clinical text. Philadelphia: Wolters Kluwer Lippincott Williams & Wilkins, 10th edition, 2013. pp. 183–97.
18.
Ruggeri RM, Vitarelli E, Barresi G, Trimarchi F, Benvenga S, Trovato M. The tyrosine kinase receptor c-met, its cognate ligand HGF and the tyrosine kinase receptor trasducers STAT3, PI3K and RHO in thyroid nodules associated with Hashimoto’s thyroiditis: an immunohistochemical characterization. Eur J Histochem. 2010;54:e24.CrossRefPubMedPubMedCentral
19.
Ruggeri RM, Vitarelli E, Barresi G, Trimarchi F, Benvenga S, Trovato M. HGF/C-MET system pathways in benign and malignant histotypes of thyroid nodules: an immunohistochemical characterization. Histol Histopathol. 2012;27:113–21.PubMed
20.
Sarlis NJ, Benvenga S. Molecular signaling in thyroid cancer. Cancer Treat Res. 2004;122:237–64.CrossRefPubMed
21.
22.
Ciampolillo A, De Tullio C, Giorgino F. The IGF-I/IGF-I receptor pathway: implications in the pathophysiology of thyroid cancer. Curr Med Chem. 2005;12:2881–91.CrossRefPubMed
23.
Maiorano E, Ciampolillo A, Viale G, Maisonneuve P, Ambrosi A, Triggiani V, Marra E, Perlino E. Insulin-like growth factor 1 expression in thyroid tumors. Appl Immunohistochem Mol Morphol. 2000;8:110–9.PubMed
24.
Malaguarnera R, Frasca F, Garozzo A, Gianì F, Pandini G, Vella V, Vigneri R, Belfiore A. Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid. J Clin Endocrinol Metab. 2011;96:766–74.CrossRefPubMed
25.
Poulaki V, Mitsiades CS, McMullan C, Sykoutri D, Fanourakis G, Kotoula V, Tseleni-Balafouta S, Koutras DA, Mitsiades N. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas. J Clin Endocrinol Metab. 2003;88:5392–8.CrossRefPubMed
26.
Belfiore A, Malaguarnera R. Insulin receptor and cancer. Endocr Relat Cancer. 2011;18:R125–47.CrossRefPubMed
27.
Ben-Shmuel S, Rostoker R, Scheinman EJ, LeRoith D. Metabolic syndrome, type 2 diabetes, and cancer: epidemiology and potential mechanisms. Handb Exp Pharmacol. 2016;233:355–72.CrossRefPubMed
28.
Hanefeld M, Pistrosch F, Bornstein SR, Birkenfeld AL. The metabolic vascular syndrome - guide to an individualized treatment. Rev Endocr Metab Disord. 2016;17:5–17.CrossRefPubMedPubMedCentral
29.
Rezzonico J, Rezzonico M, Pusiol E, Pitoia F, Niepomniszcze H. Introducing the thyroid gland as another victim of the insulin resistance syndrome. Thyroid. 2008;18:461–4.CrossRefPubMed
30.
Rezzonico J, Rezzonico M, Pusiol E, Pitoia F, Niepomniszcze H. Metformin treatment for small benign thyroid nodules in patients with insulin resistance. Metab Syndr Relat Disord. 2011;9:69–75.CrossRefPubMed
31.
Rezzonico JN, Rezzonico M, Pusiol E, Pitoia F, Niepomniszcze H. Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma. Metab Syndr Relat Disord. 2009;7:375–80.CrossRefPubMed
32.
Yasar HY, Ertuğrul O, Ertuğrul B, Ertuğrul D, Sahin M. Insulin resistance in nodular thyroid disease. Endocr Res. 2011;36:167–74.CrossRefPubMed
33.
Chen G, Xu S, Renko K, Derwahl M. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J Clin Endocrinol Metab. 2012;97:E510–20.CrossRefPubMed
34.
Oh JY, Sung YA, Lee HJ. Elevated thyroid stimulating hormone levels are associated with metabolic syndrome in euthyroid young women. Korean J Intern Med. 2013;28:180–6.CrossRefPubMedPubMedCentral
35.
Park HT, Cho GJ, Ahn KH, Shin JH, Hong SC, Kim T, Hur JY, Kim YT, Lee KW, Kim SH. Thyroid stimulating hormone is associated with metabolic syndrome in euthyroid postmenopausal women. Maturitas. 2009;62:301–5.CrossRefPubMed
36.
Garduño-Garcia Jde J, Alvirde-Garcia U, López-Carrasco G, Padilla Mendoza ME, Mehta R, Arellano-Campos O, Choza R, Sauque L, Garay-Sevilla ME, Malacara JM, Gomez-Perez FJ, Aguilar-Salinas CA. TSH and free thyroxine concentrations are associated with differing metabolic markers in euthyroid subjects. Eur J Endocrinol. 2010;163:273–8.CrossRefPubMed
37.
Roos A, Bakker SJ, Links TP, Gans RO, Wolffenbuttel BH. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab. 2007;92:491–6.CrossRefPubMed
38.
Lin SY, Wang WY, Liu PH, Lai WA, Sheu WH. Lower serum free thyroxine levels are associated with the metabolic syndrome. Metabolism. 2005;54:1524–8.CrossRefPubMed
39.
Uzunlulu M, Yorulmaz E, Oguz A. Prevalence of subclinical hypothyroidism in patients with metabolic syndrome. Endocr J. 2007;54:71–6.CrossRefPubMed
40.
Shantha GP, Kumar AA, Jeyachandran V, Rajamanickam D, Rajkumar K, Salim S, Subramanian KK, Natesan S. Association between primary hypothyroidism and metabolic syndrome and the role of C reactive protein: a cross-sectional study from South India. Thyroid Res. 2009;2:2.CrossRefPubMedPubMedCentral
41.
Giandalia A, Russo GT, Romeo EL, Alibrandi A, Villari P, Mirto AA, Armentano G, Benvenga S, Cucinotta D. Influence of high-normal serum TSH levels on major cardiovascular risk factors and visceral adiposity index in euthyroid type 2 diabetic subjects. Endocrine. 2014;47:152–60.CrossRefPubMed
42.
El-Eshmawy MM, Abd El-Hafez HA, El Shabrawy WO, Abdel Aal IA. Subclinical hypothyroidism is independently associated with microalbuminuria in a cohort of prediabetic Egyptian adults. Diabetes Metab J. 2013;37:450–7.CrossRefPubMedPubMedCentral
43.
Al Sayed A, Al Ali N, Bo Abbas Y, Alfadhli E. Subclinical hypothyroidism is associated with early insulin resistance in Kuwaiti women. Endocr J. 2006;53:653–7.CrossRefPubMed
44.
Billic-Komarica E, Becirag A, Junuzovic D. The importance of HBA1c control in patients with subclinical hypothyroidism. Mater Sociomed. 2012;24:212–9.CrossRefPubMedPubMedCentral
45.
Wang C. The relationship between type 2 diabetes mellitus and related thyroid diseases. J Diabetes Res. 2013;2013:390534.PubMedPubMedCentral
46.
47.
Chidakel A, Mentuccia D, Celi FS. Peripheral metabolism of thyroid hormone and glucose homeostasis. Thyroid. 2005;15:899–903.CrossRefPubMed
48.
Benvenga S, Pintaudi B, Vita R, Di Vieste G, Di Benedetto A. Serum thyroid hormone autoantibodies in type 1 diabetes mellitus. J Clin Endocrinol Metab. 2015;100:1870–8.CrossRefPubMed
49.
Nordio M, Pajalich R. Combined treatment with myo-inositol and selenium ensures euthyroidism in subclinical hypothyroidism patients with autoimmune thyroiditis. J Thyr Research. 2013;2013:424163.
50.
51.
Koch CA, Diamanti-Kandarakis E. Introduction to endocrine disrupting chemicals - is it time to act? Rev Endocr Metab Disord. 2015;16:269–70.CrossRefPubMed
52.
Duntas LH, Mantzou E, Koutras DA. Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis. Eur J Endocrinol. 2003;148:389–93.CrossRefPubMed
53.
Mazokopakis EE, Papadakis JA, Papadomanolaki MG, Batistakis AG, Giannakopoulos TG, Protopapadakis EE, Ganotakis ES. Effects of 12 months treatment with L-selenomethionine on serum anti-TPO levels in patients with Hashimoto’s thyroiditis. Thyroid. 2007;17:609–12.CrossRefPubMed
54.
Balázs C. The effect of selenium therapy on autoimmune thyroiditis. Orv Hetil. 2008;149:1227–32.CrossRefPubMed
55.
Zhu L, Bai X, Teng WP, Shan ZY, Wang WW, Fan CL, Wang H, Zhang HM. Effects of selenium supplementation on antibodies of autoimmune thyroiditis. Zhonghua Yi Xue Za Zhi. 2012;92:2256–60.PubMed
56.
Negro R, Greek G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H. The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. J Clin Endocrinol Metab. 2007;92:1263–8.CrossRefPubMed
57.
58.
Fruman DA, Bismuth G. Fine tuning the immune response with PI3K. Immunol Rev. 2009;228:253–72.CrossRefPubMed
59.
Kashiwada M, Lu P, Rothman PB. PIP3 pathway in regulatory T cells and autoimmunity. Immunol Res. 2007;39:194–224.CrossRefPubMed
60.
Séïté JF, Goutsmedt C, Youinou P, Pers JO, Hillion S. Intravenous immunoglobulin induces a functional silencing program similar to anergy in human B cells. J Allergy Clin Immunol. 2014;133:181–8–e1–9.CrossRef
61.
Tsubata T. Role of inhibitory BCR co-receptors in immunity. Infect Disord Drug Targets. 2012;12:181–90.CrossRefPubMed
62.
63.
Pouillon V, Maréchal Y, Frippiat C, Erneux C, Schurmans S. Inositol 1,4,5-trisphosphate 3-kinase B (Itpkb) controls survival, proliferation and cytokine production in mouse peripheral T cells. Adv Biol Regul. 2013;53:39–50.CrossRefPubMed
64.
Wang Y, Murakami Y, Yasui T, Wakana S, Kikutani H, Kinoshita T, Maeda Y. Significance of glycosylphosphatidylinositol-anchored protein enrichment in lipid rafts for the control of autoimmunity. J Biol Chem. 2013;288:25490–9.CrossRefPubMedPubMedCentral
65.
66.
Janssen OE, Mehlmauer N, Hahn S, Offner AH, Gartner R. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol. 2004;150:363–9.CrossRefPubMed
67.
Garelli S, Masiero S, Plebani M, Chen S, Furmaniak J, Armanini D, Betterle C. High prevalence of chronic thyroiditis in patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2013;169:248–51.CrossRefPubMed
68.
Du D, Li X. The relationship between thyroiditis and polycystic ovary syndrome: a meta-analysis. Int J Clin Exp Med. 2013;6:880–9.PubMedPubMedCentral
69.
Ott J, Aust S, Kurz C, Kurz C, Nouri K, Wirth S, Huber JC, Mayerhofer K. Elevated antithyroid peroxidase antibodies indicating Hashimoto’s thyroiditis are associated with the treatment response in infertile women with polycystic ovary syndrome. Fertil Steril. 2010;94:2895–7.CrossRefPubMed
70.
Sinha U, Sinharay K, Saha S, Longkumer TA, Baul SN, Pal SK. Thyroid disorders in polycystic ovarian syndrome subjects: a tertiary hospital based cross-sectional study from eastern India. Indian J Endocrinol Metab. 2013;17:304–9.CrossRefPubMedPubMedCentral
71.
Palioura E, Diamanti-Kandarakis E. Polycystic ovary syndrome (PCOS) and endocrine disrupting chemicals (EDCs). Rev Endocr Metab Disord. 2015;16:365–71.CrossRefPubMed
72.
Mutinati M, Desantis S, Rizzo A, Zizza S, Ventriglia G, Pantaleo M, Sciorsci RL. Localization of thyrotropin receptor and thyroglobulin in the bovine corpus luteum. Anim Reprod Sci. 2010;118:1–6.CrossRefPubMed
73.
Katulande P, Kariyawasam SS, Senanayake HM, Weerakkodi M. Multicystic ovaries and pituitary pseudo-adenoma associated with primary hypothyroidism. J Obstet Gynaecol. 2013;33:17–9.CrossRefPubMed
74.
Li Q, Yang G, Wang Y, Zhang X, Sang Q, Wang H, Zhao X, Xing Q, He L, Wang L. Common genetic variation in the 3′-untranslated region of gonadotropin-releasing hormone receptor regulates gene expression in cella and is associated with thyroid function, insulin secretion as well as insulin sensitivity in polycystic ovary syndrome patients. Hum Genet. 2011;129:553–61.CrossRefPubMed
75.
Zou S, Sang Q, Wang H, Feng R, Li Q, Zhao X, Xing Q, Jin L, He L, Wang L. Common genetic variation in CYP1B1 is associated with concentrations of T4, FT3 and FT4 in the sera of polycystic ovary syndrome patients. Mol Biol Rep. 2013;40:3315–20.CrossRefPubMed
76.
Ghosh S, Kabir SN, Pakrashi A, Chatterjee S, Chakravarty B. Subclinical hypothyroidism: a determinant of polycystic ovary syndrome. Horm Res. 1993;39:61–6.CrossRefPubMed
77.
Muderris II, Boztosun A, Oner G, Bayram F. Effect of thyroid hormone replacement therapy on ovarian volume and androgen hormones in patients with untreated primary hypothyroidism. Ann Saudi Med. 2011;31:145–51.CrossRefPubMedPubMedCentral
78.
Ganie MA, Marwaha RK, Aggarwal R, Singh S. High prevalence of polycystic ovary syndrome characteristics in girls with euthyroid chronic lymphocytic thyroiditis: a case-control study. Eur J Endocrinol. 2010;162:1117–22.CrossRefPubMed
79.
80.
81.
Antonelli A, Fallahi P, Ferrari SM, Pupilli C, d’Annunzio G, Lorini R, Vanelli M, Ferrannini E. Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed type 1 diabetes: a longitudinal study. Diabet Med. 2008;25:1349–53.PubMed
82.
Antonelli A, Ferri C, Fallahi P, Cazzato M, Ferrari SM, Sebastiani M, Ferrannini E. Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis. Eur J Endocrinol. 2007;156:431–7.CrossRefPubMed
83.
Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Carpi A, Nicolini A, Ferrannini E. Alpha-chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis. Metabolism. 2008;57:1270–7.CrossRefPubMed
84.
Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C, Fallahi P. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev. 2014;13:272–80.CrossRefPubMed
85.
Kung AW, Lau KS, Wong NS. Interferon-gamma increases intracellular calcium and inositol phosphates in primary human thyroid cell culture. Endocrinology. 1995;136:5028–33.PubMed
86.
Kung AW, Lau KS. Gamma-interferon activates a nuclear protein that binds to the gamma-interferon activation site of the thyroglobulin gene. J Mol Endocrinol. 1998;20:293–8.CrossRefPubMed
87.
Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol. 2005;174:827–34.CrossRefPubMed
88.
Morrison CD, Brannigan RE. Metabolic syndrome and infertility in men. Best Pract Res Clin Obstet Gynaecol. 2015;29:507–15.CrossRefPubMed
89.
Traish AM, Zitzmann M. The complex and multifactorial relationship between testosterone deficiency (TD), obesity and vascular disease. Rev Endocr Metab Disord. 2015;16:249–68.CrossRefPubMed
90.
Ullah MI, Washington T, Kazi M, Tamanna S, Koch CA. Testosterone deficiency as a risk factor for cardiovascular disease. Horm Metab Res. 2011;43:153–64.CrossRefPubMed
91.
Costa RR, Varanda WA, Franci CR. A calcium-induced calcium release mechanism supports luteinizing hormone-induced testosterone secretion in mouse Leydig cells. Am J Physiol Cell Physiol. 2010;299:C316–23.CrossRefPubMed
92.
Rothschild G, Sottas CM, Kissel H, Agosti V, Manova K, Hardy MP, Besmer P. A role for kit receptor signaling in Leydig cell steroidogenesis. Biol Reprod. 2003;69:925–32.CrossRefPubMed
93.
Blume-Jensen P, Jiang G, Hyman R, Lee KF, O’Gorman S, Hunter T. Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3′-kinase is essential for male fertility. Nat Genet. 2000;24:157–62.CrossRefPubMed
94.
Casulari LA, Caldas AD. Domingues Casulari Motta L. Lofrano-Porto A Effects of metformin and short-term lifestyle modification on the improvement of male hypogonadism associated with metabolic syndrome Minerva Endocrinol. 2010;35:145–51.PubMed
95.
Bevilacqua A, Carlomagno G, Gerli S, Montanino Oliva M, Devroey P, Lanzone A, Soulange C, Facchinetti F, Carlo Di Renzo G, Bizzarri M, Hod M, Cavalli P, D’Anna R, Benvenga S, Chiu TT, Kamenov ZA. Results from the international consensus conference on myo-inositol and D-chiro-inositol in obstetrics and gynecology. Gynecol Endocrinol. 2015;31:441–6.CrossRefPubMed
Metadaten
Titel
Inositol(s) in thyroid function, growth and autoimmunity
verfasst von
Salvatore Benvenga
Alessandro Antonelli
Publikationsdatum
18.06.2016
Verlag
Springer US
Erschienen in
Reviews in Endocrine and Metabolic Disorders / Ausgabe 4/2016
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-016-9370-3

Weitere Artikel der Ausgabe 4/2016

Reviews in Endocrine and Metabolic Disorders 4/2016 Zur Ausgabe

ReviewPaper

Conservation in the phylum of the local homology of apolipoproteins with the thyroid hormone plasma carriers

ReviewPaper

Hypothyroid myopathy: A peculiar clinical presentation of thyroid failure. Review of the literature

ReviewPaper

The micropapillary/hobnail variant of papillary thyroid carcinoma: A review of series described in the literature compared to a series from one southern Italy pathology institution

ReviewPaper

Thyroid hormone regulation of adult intestinal stem cells: Implications on intestinal development and homeostasis

EditorialNotes

A journey from brain to muscle across the thyroid continent

ReviewPaper

Molecular mimicry and autoimmune thyroid disease

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

26.04.2024 | Hüft-TEP | Nachrichten

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Allergien und Intoleranzreaktionen | Nachrichten

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise